|
1
|
Barillé-Nion S, Barlogie B, Bataille R, et
al: Advances in biology and therapy of multiple myeloma. Hematology
Am Soc Hematol Educ Program. 2003:248–278. 2003. View Article : Google Scholar
|
|
2
|
Kuehl WM and Bergsagel PL: Multiple
myeloma: evolving genetic events and host interactions. Nat Rev
Cancer. 2:175–187. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Richardson PG, Mitsiades C, Schlossman R,
Munshi N and Anderson K: New drugs for myeloma. Oncologist.
12:664–689. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lentzsch S, O’Sullivan A, Kennedy RC, et
al: Combination of bendamustine, lenalidomide, and dexamethasone
(BLD) in patients with relapsed or refractory multiple myeloma is
feasible and highly effective: results of phase 1/2 open-label,
dose escalation study. Blood. 119:4608–4613. 2012. View Article : Google Scholar
|
|
5
|
Palumbo A, Attal M and Roussel M: Shifts
in the therapeutic paradigm for patients newly diagnosed with
multiple myeloma: maintenance therapy and overall survival. Clin
Cancer Res. 17:1253–1263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lauta VM: A review of the cytokine network
in multiple myeloma: diagnostic, prognostic, and therapeutic
implications. Cancer. 97:2440–2452. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trikha M, Corringham R, Klein B and Rossi
JF: Targeted anti-interleukin-6 monoclonal antibody therapy for
cancer: a review of the rationale and clinical evidence. Clin
Cancer Res. 9:4653–4665. 2003.PubMed/NCBI
|
|
8
|
Hideshima T, Nakamura N, Chauhan D and
Anderson KC: Biologic sequelae of interleukin-6 induced PI3-K/Akt
signaling in multiple myeloma. Oncogene. 20:5991–6000. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ramgolam V, Ang SG, Lai YH, Loh CS and Yap
HK: Traditional Chinese medicines as immunosuppressive agents. Ann
Acad Med Singapore. 29:11–16. 2000.PubMed/NCBI
|
|
10
|
Küpeli E, Koşar M, Yeşilada E, Hüsnü K and
Başer C: A comparative study on the anti-inflammatory,
antinociceptive and antipyretic effects of isoquinoline alkaloids
from the roots of Turkish Berberis species. Life Sci.
72:645–657. 2002.PubMed/NCBI
|
|
11
|
Zhao XY, He ZW, Wu D and Xu RZ: Berbamine
selectively induces apoptosis of human acute promyelocytic leukemia
cells via survivin-mediated pathway. Chin Med J (Engl).
120:802–806. 2007.PubMed/NCBI
|
|
12
|
Wang GY, Zhang JW, Lu QH, Xu RZ and Dong
QH: Berbamine induces apoptosis in human hepatoma cell line
SMMC7721 by loss in mitochondrial transmembrane potential and
caspase activation. J Zhejiang Univ Sci B. 8:248–255. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu R, Dong Q, Yu Y, et al: Berbamine: a
novel inhibitor of bcr/abl fusion gene with potent anti-leukemia
activity. Leuk Res. 30:17–23. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li BY, Fu B, Zhao YL and Li WH: Effects of
berbamine on intracellular calcium concentration in cultured HeLa
cells. Zhongguo Yao Li Xue Bao. 20:1011–1014. 1999.PubMed/NCBI
|
|
15
|
Du HP, Shen JK, Yang M, et al:
4-Chlorobenzoyl berbamine induces apoptosis and G2/M cell cycle
arrest through the PI3K/Akt and NF-κB signal pathway in lymphoma
cells. Oncol Rep. 23:709–716. 2010.PubMed/NCBI
|
|
16
|
Cui Y, Xu M, Mao J, Ouyang J, Xu R and Yu
Y: Synthesis of berbamine acetyl glycosides and evaluation of
antitumor activity. Eur J Med Chem. 54:867–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vermes I, Haanen C, Steffens-Nakken H and
Reutelingsperger C: A novel assay for apoptosis. Flow cytometric
detection of phosphatidylserine expression on early apoptotic cells
using fluorescein labelled Annexin V. J Immunol Methods. 184:39–51.
1995. View Article : Google Scholar
|
|
18
|
Dorée M and Hunt T: From Cdc2 to Cdk1:
when did the cell cycle kinase join its cyclin partner? J Cell Sci.
115:2461–2464. 2002.PubMed/NCBI
|
|
19
|
Galea CA, Wang Y, Sivakolundu SG and
Kriwacki RW: Regulation of cell division by intrinsically
unstructured proteins: intrinsic flexibility, modularity, and
signaling conduits. Biochemistry. 47:7598–7609. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toyoshima-Morimoto F, Taniguchi E, Shinya
N, Iwamatsu A and Nishida E: Polo-like kinase 1 phosphorylates
cyclin B1 and targets it to the nucleus during prophase. Nature.
410:215–220. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Klein B, Zhang XG, Lu ZY and Bataille R:
Interleukin-6 in human multiple myeloma. Blood. 85:863–872.
1995.PubMed/NCBI
|
|
22
|
Kovacs E: Multiple myeloma and B cell
lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA),
and GP130 antagonist (GP130A) using various parameters in an in
vitro model. Sc World J. 6:888–898. 2006. View Article : Google Scholar
|
|
23
|
Guo Y, Xu F, Lu T, Duan Z and Zhang Z:
Interleukin-6 signaling pathway in targeted therapy for cancer.
Cancer Treat Rev. 38:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Petros AM, Olejniczak ET and Fesik SW:
Structural biology of the Bcl-2 family of proteins. Biochim Biophys
Acta. 1644:83–94. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Willis SN, Fletcher JI, Kaufmann T, et al:
Apoptosis initiated when BH3 ligands engage multiple Bcl-2
homologs, not Bax or Bak. Science. 315:856–859. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hübner A, Barrett T, Flavell RA and Davis
RJ: Multisite phosphorylation regulates Bim stability and apoptotic
activity. Mol Cell. 30:415–425. 2008.PubMed/NCBI
|
|
27
|
Brunet A, Bonni A, Zigmond MJ, et al: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barreyro FJ, Kobayashi S, Bronk SF,
Werneburg NW, Malhi H and Gores GJ: Transcriptional regulation of
Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem.
282:27141–27154. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Modur V, Nagarajan R, Evers BM and
Milbrandt J: FOXO proteins regulate tumor necrosis factor-related
apoptosis inducing ligand expression. Implications for PTEN
mutation in prostate cancer. J Biol Chem. 277:47928–47937. 2002.
View Article : Google Scholar
|
|
30
|
Burgering BM and Kops GJ: Cell cycle and
death control: long live Forkheads. Trends Biochem Sci. 27:352–360.
2002. View Article : Google Scholar : PubMed/NCBI
|
